What is a clinical trial?
Before a new drug is released to the market, it takes a long time and a lot of research and testing.
New drugs developed by pharmaceutical companies require approval from the Ministry of Health, Labor and Welfare, and clinical trials are conducted to obtain this approval. Clinical trials are conducted in accordance with standards set by the Ministry of Health, Labor and Welfare (standards for conducting clinical trials of pharmaceuticals). Clinical trials for anticancer drugs have the following stages (phases), and development proceeds in order, with safety and efficacy being confirmed at each stage.
Phase I
We examine how candidate drug substances behave in the body and whether their side effects are tolerable and can be used without problems.
Phase II
A relatively small number of patients are studied to examine the efficacy and safety of a drug candidate.
The dosage and method of administration will be considered.
Phase III
This is a relatively large-scale trial, involving a larger number of patients than Phase II trials.
Typically, the study will compare the treatment with the current standard of care.
Phase IV
These are conducted after a drug has been approved by the Ministry of Health, Labor and Welfare and is on the market, and are called "post-marketing clinical trials."
We will post information about cancer clinical trials being conducted at our hospital.
Not everyone can participate in clinical trials. Each clinical trial has its own conditions, so please inquire with the relevant department.
Clinical Trials and Research Center website also provides information about clinical trials.
Current (publicly available) cancer clinical trials
As of October 1, 2026
| Clinical department | Target diseases and indications | Assignment name |
Breast Surgery |
Programmed death-ligand (PD-L1)-positive locally recurrent inoperable or metastatic triple-negative breast cancer |
TROPION-Breast05 is a phase III open-label randomized trial commissioned by Daiichi Sankyo Co., Ltd. to compare datopotamab deruxtecan (Dato-DXd) monotherapy or combination therapy with durvalumab with physician-selective chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) and pembrolizumab in patients with locally recurrent, unresectable, or metastatic triple-negative breast cancer that is positive for the Programmed Death-Ligand (PD-L1). |
Breast Surgery |
Patients with advanced breast cancer who have BRCA1, BRCA2, or PALB2 mutations and are HR positive, HER2 negative (IHC 0, 1+, 2+/ISH negative) |
A Phase III study of saruparib (AZD5305) plus camizestrant in patients with HR-positive, HER2-negative advanced breast cancer sponsored by AstraZeneca K.K. |
Breast Surgery |
Triple-negative breast cancer that has not achieved a pathological complete response |
A Phase 3 study sponsored by MSD K.K. comparing MK-2870 plus pembrolizumab to investigator's choice of treatment in patients with triple-negative breast cancer who have not achieved a pathological complete response |
Breast Surgery |
Metastatic cancer patients |
Phase Ib and Phase II clinical trials of zongertinib (BI 1810631) in combination with trastuzumab deruxtecan or trastuzumab emtansine in patients with metastatic cancer, commissioned by IQVIA Services Japan Co., Ltd. (Domestic Clinical Trial Administrator) |
Breast Surgery |
Unresectable or metastatic triple-negative breast cancer (PD-L1CPS < 10) |
A Phase 3 trial commissioned by MSD K.K. to compare MK-2870 (sac-TMT) monotherapy with MK-3475 (pembrolizumab) combination therapy as first-line treatment for unresectable or metastatic triple-negative breast cancer (PD-L1 CPS <10), compared with treatment selected by the investigator. |
Breast Surgery |
Locally advanced or metastatic solid tumors with PIK3CA mutation, hormone receptor-positive, HER2-negative, inoperable or recurrent breast cancer |
Phase I/II trial commissioned by Chugai Pharmaceutical Co., Ltd. |
gynecology |
uterine cancer |
Phase III trial of AZD8205 in endometrial cancer patients, commissioned by AstraZeneca K.K. |
Breast Surgery |
Patients with PIK3CA mutations, endocrine-sensitive hormone receptor-positive, HER2-negative breast cancer |
A Phase III trial of inavolisib (R07113755) in patients with PIK3CA mutations, endocrine-sensitive hormone receptor-positive, HER2-negative breast cancer, commissioned by Chugai Pharmaceutical Co., Ltd. |
Gastroenterological Surgery |
Solid cancer |
REGN7508 (ROXI-CAT-I) as primary prevention of CAT in patients with solid tumors, as requested by Regeneron Japan Co., Ltd. |
Hematology-oncology |
Multiple myeloma |
Phase III trial of LINVOSELTAMAB (REGN5458) for multiple myeloma, commissioned by Parexel International Co., Ltd. (domestic clinical trial administrator). |
| Hematology-oncology | Relapsed or refractory diffuse large B-cell lymphoma |
A Phase II/III trial commissioned by MSD K.K. to compare MK-2140 + standard treatment with standard treatment for relapsed or refractory diffuse large B-cell lymphoma. |
| Breast Surgery | Patients with advanced or metastatic HR+/HER2- breast cancer who have not received prior treatment for advanced or metastatic breast cancer. |
A comparison of BGB-43395 + letrozole and CDK4/6i + letrozole in patients with advanced or metastatic HR+/HER2- breast cancer who had not received prior treatment, as requested by B1 Medicines LLC. |
| Breast Surgery | ER+/HER2- breast cancer patients |
(Domestic Clinical Trial Administrator) Phase II trial of Elacestrant in ER+/HER2- breast cancer patients, commissioned by CMIC Corporation. |
Breast Surgery |
Patients with hormone receptor-positive, HER2-low or very-low expression unresectable or metastatic breast cancer |
A Phase Ib/II, multicenter, open-label, regimen determination and dose-expansion study (HERTHENA-Breast02) commissioned by Medpace Japan Co., Ltd. to evaluate the safety, tolerability, antitumor efficacy, and optimal regimen of combination therapy with patritumab deruxtecan (HER3-DXd) and trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive, HER2-low or very-low expression unresectable or metastatic breast cancer. |
Obstetrics and Gynecology |
Platinum-sensitive recurrent ovarian cancer |
Phase III trial of Rinatabart Sesutecan in patients with platinum-sensitive recurrent ovarian cancer, commissioned by ICON Clinical Research LLC (domestic clinical trial administrator). |
